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Abstract  
 
Transgender women experience disproportionate risk of HIV acquisition and transmission. We piloted 
‘Sheroes’, a peer-led group-level intervention for transgender women of any HIV status emphasizing 
empowerment and gender affirmation to reduce HIV risk behaviors and increase social support. Participants 
(N=77) were randomized to Sheroes (n=39) or a time- and attention-matched control (n=38). Sheroes is 5 
weekly group sessions; topics include sexuality, communication, gender transition, and coping skills. Control 
participants attended 5 weekly group movie sessions. At 6-month follow up, HIV-negative and unknown status 
Sheroes participants reported reductions in condomless intercourse and improved social support compared to 
control. Among participants living with HIV, both the control and intervention groups reduced their total number 
of sex partners; this change was sustained at 6-month follow-up for Sheroes participants but not for control 
participants relative to baseline. Sheroes was deemed highly feasible and acceptable to participants; findings 
support preliminary efficacy of Sheroes.  
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Background 
 Transgender women, although resourceful and resilient, are a highly vulnerable and marginalized 
population in the United States (US) as well as globally, experiencing high rates of stigma, discrimination, and 
violence (1-5). Consequently, given the association of negative health outcomes with stigma and 
discrimination, transgender women experience severe health disparities across a number of outcomes, 
including HIV (6-9). Although no national data yet exist in the US, a meta-analysis found that 28% of 
transgender women tested positive for HIV (7). In California, transgender female clients of publicly-funded 
counseling and testing sites have higher rates of HIV diagnosis (6%) than all other risk categories, including 
MSM (4%) and partners of people living with HIV (5%), and African American transgender women have a 
particularly high rate of HIV diagnosis (29%) (10). Estimates from other urban centers in the US similarly 
suggest that HIV prevalence rates among transgender women are among the highest of all key populations, 
especially for transgender women of color, and African American transgender women are most severely 
impacted (8, 11, 12).  
     Despite high HIV prevalence, transgender women frequently underestimate their risk of acquiring or 
transmitting HIV and report low rates of HIV testing (6). They report engaging in multiple types of risk, including 
unprotected receptive anal sex with multiple partners, sex under the influence of drugs and alcohol, sex work, 
and sharing needles for injection drugs, hormones, and silicone (as well as other substances) for body 
modification purposes (13-18). The previously mentioned meta-analysis found that almost half (44%) of 
transgender women reported condomless receptive anal intercourse, with most reported with sex work clients 
(39%) and primary partners (37%) (7). Sex under the influence of drugs and/or alcohol is one of the most 
commonly cited sexual risk factors among transgender women, as it often leads to risky sex (11). Among 
transgender women, condomless sex is reported to be especially prevalent with primary partners (11, 19), but 
is also reported with paying and casual partners (20, 21).   
 Despite high HIV prevalence, public health intervention research has produced few culturally specific, 
evidence-based HIV prevention interventions for transgender women and none are group-level interventions 
for adult transgender women. Group-level interventions for cisgender (i.e. non-transgender) women living with 
HIV have been shown to decrease sexual risk behavior (22), enhance self-esteem, and increase levels of 
social support within communities that often experience social isolation (23). For women living with HIV, groups 
can be a supportive environment within which to practice disclosure of their HIV status (23).  Transgender 
women are likely to benefit in similar ways from a group-level intervention, but interventions specifically 
designed for transgender women are necessary to address their unique needs and social context. 
Conceptualizing transgender women’s unique context of HIV risk, especially centering the perspective 
of transgender women of color, is critical to developing effective prevention and treatment strategies. Based on 
the Model of Gender Affirmation, we developed ‘Sheroes’, a community-led group-level HIV intervention for 
transgender women of any HIV status with an emphasis on the lived experiences of transgender women of 
color (24). The Sheroes intervention was developed in collaboration with transgender community members, 
members of a community advisory board, and staff of the Center of Excellence for Transgender Health at the 
University of California, San Francisco, all of which included a majority of transgender women of color. The 
name ‘Sheroes’ (i.e. “She + Hero”) was suggested by a community member who participated in our formative 
work, and the name was then endorsed by the advisory groups.  
The Model of Gender Affirmation was developed to contextualize risk behavior among transgender 
women of color (25). Building upon Diaz’s model developed with Latino MSM, which clarifies how internalized 
oppression leads to sex in high-risk contexts (26), combined with Major & O’Brien’s identity threat model of 
stigma and objectification theory (27), the Model of Gender Affirmation aims to clarify how stigma and 
oppression lead to HIV-related risk behaviors among transgender women. The Model of Gender Affirmation 
illustrates how social oppression decreases access to gender affirmation while psychological distress 
increases the need for gender affirmation, leading to identity threat (Figure 1). Attempts to decrease the threat 
then happen in high risk contexts, where risk behavior is more likely (13). The Sheroes intervention aims to 
decrease identity threat by increasing access to gender affirmation. Gender affirmation was integrated into the 
intervention through role modeling, group discussions, gender-affirming interactive exercises, and the 
introduction of a ‘Shero’ in each session to provide empowering examples of transgender women of color in 
history and current events. In addition to being informed by the Model of Gender Affirmation, Sheroes was 
shaped by formative qualitative data that guided decisions about how gender affirmation was integrated into 
the intervention (25).  
The primary goal of Sheroes is to decrease risk of HIV acquisition or transmission among transgender 
women by increasing access to gender affirmation through increasing access to health care, including 
transition-related care (such as hormone therapy and surgeries) as well as HIV prevention and treatment, and 
increasing social support through community building. Social support includes fostering alliances between 
transgender women through community building and empowering relationships via creation of a “sisterhood” of 
transgender women who have completed the intervention. Themes from transgender women’s experiences are 
woven throughout the intervention to maximize the cultural relevance, and thus the efficacy, of the intervention 
(see Table 1). Sheroes consists of 5 group sessions of 6-8 participants conducted weekly. Sessions were 
conducted by two trained peer co-facilitators who were transgender women of color; sessions consist of group 
discussions and interactive group activities.    
The aim of this study was to conduct a pilot randomized controlled trial (RCT) to examine the feasibility 
and acceptability of the Sheroes intervention and examine preliminary data on the efficacy of Sheroes to 
impact the primary outcomes of reducing sexual risk behavior and increasing social support. 
Methods  
Study design and participants. The pilot randomized controlled trial was conducted in San Francisco, 
California, from August 2014 to October 2015. Participants were recruited from community-based venues such 
as transgender-serving community-based organizations, clinics, and social venues, using in-person 
recruitment strategies and flyering. Participants who previously provided consent to be contacted for research 
purposes during prior studies were also contacted using their preferred method (email or phone) by either the 
research assistants or the PI and informed about the study. To be eligible, self-identified transgender women 
were required to be at least 18 years of age and report condomless sex in the past 3 months. HIV status was 
not a criterion for eligibility. To be screened for eligibility, participants completed a survey inquiring about 
demographics, sexual risk behavior, HIV status, mental health, and substance use. The eligibility survey also 
served as the baseline survey for those who were deemed eligible and enrolled. Participant eligibility was 
flagged by the computerized survey using a code that appeared when the participant completed the 
survey. The research assistant then offered eligible and interested transgender women an opportunity to enroll 
in the pilot RCT; participants were informed that, upon enrollment, they would be randomized to either the 
Sheroes intervention or a movie night. Informed consent was obtained from all participants. Enrolled 
participants were stratified by HIV status and randomized by computer to receive either the 5-session Sheroes 
intervention or a time- and attention-matched control experience. Randomization was stratified by HIV status 
and conducted in SAS 9.4 using block randomization with block sizes of two. Peer facilitators received 25 
hours of initial training in the Sheroes intervention as well as ongoing supervision which provided opportunities 
to reinforce concepts and skills from the initial training. The time- and attention-matched control condition 
consisted of a movie night that was matched to the intervention sessions by number and length of sessions 
and group size. Participants in the control group watched a standardized set of movies that were deemed by 
our Community Advisory Board to be of interest but without content that overlapped with the Sheroes 
intervention. A brief facilitated discussion followed each movie night session, again with careful attention to 
avoid content that overlapped with the intervention. If randomized, participants were given a schedule of either 
the intervention or control sessions based on the condition to which they were assigned. Participants received 
$40 cash reimbursement for their participation in each assessment visit. An additional $40 bonus incentive was 
offered to participants who completed all 5 sessions. Sheroes participants were invited to complete satisfaction 
surveys at each session they attended and to participate in a brief post-intervention qualitative interview. The 
study was approved by the Institutional Review Board at the University of California, San Francisco. 
Measures. Participants completed study assessments at baseline and at 3- and 6- months post-randomization.  
Assessments consisted of computer-assisted self-administered quantitative surveys using RedCAP (28). The 
primary outcomes for this study were number of partners with whom participants reported engaging in 
condomless receptive anal sex and self-reported social support, measured using the Social Support 
Questionnaire (SSQ-6) (29).  A sample question from the SSQ-6 is “Whom can you count on to console you 
when you are very upset?” Each SSQ-6 item is followed by the question “How satisfied are you with this type 
of support?” Feasibility measures were determined using guidance from the literature on feasibility pilot studies 
(30, 31). To evaluate feasibility, detailed process records were kept regarding the number and demographic 
characteristics of individuals who participated in each session and the amount of staff time devoted to 
recruitment and coordination of each session. Fidelity was monitored using checklists that the peer facilitators 
would complete at the end of each session to indicate whether all components of the session were 
implemented. Portions of the audio recordings of the intervention sessions were reviewed at random by the 
supervisor to ensure fidelity and guide ongoing training for the peer facilitators. To assess acceptability, we 
administered the Client Satisfaction Questionnaire (CSQ-3) (32) to solicit participant ratings of satisfaction with 
each session, overall satisfaction with the Sheroes intervention, and the likelihood that they would recommend 
the program to others, in addition to an open-ended question that solicited free text feedback. After the final 
Sheroes session, a research assistant (who was not involved in facilitating the Sheroes sessions) conducted 
audio-recorded brief (lasting 20 minutes or less) qualitative feedback sessions in which participants described 
their experiences with Sheroes and provided suggestions for improvements.  
Statistical Analysis. Descriptive statistics were calculated using SAS v9.4. Preliminary outcome analyses 
followed an intent-to-treat approach and were performed using generalized linear mixed models (GLLMs) in 
Stata v15.1 stratified by HIV serostatus containing fixed effects for group (control, intervention), time (baseline, 
3- month follow up, 6-month follow up), and their interaction. Counts of numbers of sex partners outcomes 
were modeled using a negative binomial distribution and log-link; the mean level of continuous social support 
was modeled using a normal distribution and identity link. Count outcome models estimated the mean numbers 
of sex partners as a function of the aforementioned fixed effects plus random intercepts via maximum 
likelihood whereas the continuous social support mean level was estimated as a function of the fixed effects 
using restricted maximum likelihood (REML) with an unstructured covariance matrix of the residuals and 
Kenward-Roger denominator degrees of freedom. Pre-specified simple main effects compared outcomes on 
time points within each group. All effects were evaluated at alpha = .05. Cases with partial outcome data were 
included in the analysis with incomplete data assuming to arise from either a missing-completely-at-random 
(MCAR) or a missing-at-random (MAR) missingness mechanism via the maximum likelihood estimation 
approach employed in the mixed models analyses.  
Results 
From August 2014 to October 2015, 137 transgender women were screened for eligibility and 77 were 
enrolled and randomly assigned to either the Sheroes intervention or a time- and attention-matched control 
group and were followed for 6 months (Figure 2). Of the 77 enrolled participants, 38 (49%) were Black/African-
American, 8 (10%) were Latina, 16 (17%) were White, and 15 (19%) were Multiracial, Native American, or 
Asian/Pacific Islander (grouped together for reporting purposes due to very low ns). The mean age of 
participants was 39 (SD = 10.6), and 35 (45.5%) reported HIV-positive serostatus at baseline. Of the 
participants living with HIV, 28 (82%) were currently using ART. There were no statistically significant 
differences between intervention and control participants at baseline (Table 2). Comparisons among treatment 
arm and demographic characteristics between those lost to follow up (N=27, 35%) and those with one or more 
follow up interviews (N=50, 65%) yielded no significant differences (lowest observed p-value was 0.28). 
Feasibility.  Feasibility of the pilot RCT was high; two part-time research assistants (who also served as the 
peer facilitators of the intervention) enrolled 77 participants over a period of 14 months. Feasibility of 
implementation of the intervention was also high; of the 39 women who were randomized to the Sheroes 
intervention, 82% (n=32) attended at least one session and 67% (n=26) participated in all five sessions. 
Sessions were implemented with high fidelity; only two of the sessions were not implemented as originally 
designed due to unexpected external interruptions (one fire alarm and one emergency unrelated to the 
intervention implementation).  
Acceptability. At the end of each of the five sessions and at the end of the intervention, women rated their 
satisfaction with Sheroes on the CSQ-3 as either ‘Extremely’ or ‘Very Satisfied’ (no ratings below Very 
Satisfied); 92% reported that they were ‘Extremely Satisfied’ with their overall experience with Sheroes. The 
lowest ratings were for the final session, in which 66% rated ‘Extremely Satisfied’ (the rest were ‘Very 
Satisfied’); qualitative feedback suggested that a desire for more sessions (and knowing that the group would 
not meet again) was a reason for several participants’ lower rating of the final session. All 24 (100%) 
participants who completed the Sheroes intervention indicated that they were ‘Extremely Likely’ to recommend 
Sheroes to others. In qualitative debriefing sessions, Sheroes participants were asked to describe their 
experiences with Sheroes and provide suggestions for improvements. For example, when asked about their 
reactions to Sheroes, participants responded: “I feel very empowered and blessed to have had this experience 
with my sisters” (37 yo AA); “I learned how to take better care of me in all kinds of ways” (31 yo AA); and “It 
helped me to feel better about myself and to want to make changes to stay healthy” (42 yo Latina). 
Primary outcomes. Among HIV-negative participants in Sheroes, there was no significant group-by-time 
interaction for the reported number of sex partners with whom participants had condomless intercourse (p=.67) 
and no significant group-by-time interaction for social support (p=.67). However, planned comparisons within 
each point indicated statistically significant reductions in the reported number of sex partners with whom 
participants had condomless intercourse (p=.007) and improved social support (p=.04) whereas number of 
partners (p=.17) and social support (p=.52) did not change over time in the control group (see Table 3). Among 
HIV-positive participants, there was no significant group-by-time interaction in the total number of sex partners 
(p=.31). Planned comparisons within each group yielded reductions in total number of sex partners over time in 
both groups (Table 3). Additional follow-up two time-point comparisons of the 6-month time point with the 
baseline time point indicated that the change was sustained at the 6-month follow-up for the Sheroes group 
(p=.04), but not for the control group relative to baseline (p=.17; see Table 3 for estimated and means and 
standard errors for each time point). 
Discussion 
We have developed and successfully piloted an innovative, group-based, peer-led, community-
informed intervention that addresses the unifying lived experiences of HIV-positive, negative, and unknown 
status adult transgender women. While this pilot RCT was not powered to test the efficacy of the intervention, a 
fact reflected in the non-significant group-by-time interaction tests, preliminary evidence suggests that Sheroes 
is a promising intervention for reducing sexual risk behavior while attending to the unique needs of transgender 
women who are at elevated risk for acquiring or transmitting HIV. A priori within-group comparisons showed 
that exposure to the intervention resulted in statistically significant reductions in reported condomless sex and 
improved social support among HIV-negative participants. A priori within-group comparisons among 
participants living with HIV showed reduced sexual risk behavior regardless of whether they participated in 
Sheroes or the control group, but those assigned to Sheroes sustained this behavior at the 6-month follow up 
while those in the control group did not. Both groups reported reduced condomless sex, which may indicate a 
high need for social support among transgender women. The element of social support may have contributed 
to a therapeutic effect even among control group participants, though beneficial effects of the control condition 
were more short-lived than those for Sheroes. Additional research with larger samples over a longer follow-up 
period is needed to evaluate this innovative strategy for reducing sexual risk among transgender women at risk 
for acquisition or transmission of HIV. Because Sheroes includes transgender women of any serostatus, it 
provides a pioneering opportunity to reduce sexual risk behaviors and prevent new HIV infections from both a 
primary and secondary prevention perspective.  
Including transgender women living with HIV and not living with HIV provided opportunities for peer-to-
peer education and mentoring around shared challenges and experiences. Peer support and mentoring is 
essential to decreasing transgender women’s sense of isolation, encouraging pride in one’s gender identity, 
and skill sharing for coping with everyday stressors. Issues of race and ethnicity are systematically addressed 
in Sheroes with special attention to their intersectionality with gender identity. Thus, integral themes from the 
lived experience of transgender women who bear a disproportionate burden of HIV are incorporated to 
maximize the cultural relevance, and thus the efficacy, of the intervention. This pilot RCT of Sheroes provided 
valuable experience and opportunity for refinement. Feedback from participants included the desire for a 
“booster” session, providing the opportunity for participants to reunite after graduation from Sheroes and check 
in with one another about challenges and issues discussed during the intervention. 
Limitations.  When interpreting these findings, several limitations should be considered. This study was 
conducted in San Francisco, an urban center in the United States that may result in limited generalizability to 
other geographic locations.  The primary outcome was self-reported, which may be subject to bias. No 
measurement of negotiated safety was measured in our assessment of sexual behavior, so the risk level of 
reported condomless sex could not be determined. The Sheroes intervention was developed around the same 
time as the introduction of PrEP, so limited content related to PrEP knowledge and uptake was integrated into 
the curriculum. At the time of this study, PrEP use among transgender women was low, but as PrEP use 
increases and access to PrEP for transgender women improves, it will be important to deliver the most current 
PrEP information and resources to transgender women who participate in Sheroes. Future larger scale 
research to test the efficacy of Sheroes should incorporate additional information and outcome measures 
related to PrEP use among participants, examine outcomes by partner type (e.g. committed, casual, paying) 
and explore potential differences in outcomes between participants of various racial and ethnic groups. Future 
efficacy studies may also seek to update and/or adapt some of the content of Sheroes in order to ensure that it 
reflects current concepts and issues related to transgender health.  
Conclusions.  This study provides preliminary evidence that Sheroes is a feasible and acceptable group-level 
intervention for mixed HIV status, adult transgender women. Future research will test the efficacy of Sheroes to 
reduce sexual risk behavior utilizing a full randomized controlled trial design. 
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Table 1. Sheroes intervention content 
 
 
 
• Each session includes sharing resources to increase participants’ access to gender affirming healthcare and services, 
including linkage to HIV/STI testing and support for engagement in HIV treatment and care 
Session Topic Objectives 
1 
Gender 
Pride 
Explore and discuss trans identities and historical figures 
Discuss gender pride and identify positive transgender role models, with a focus on transwomen of 
color 
Introduce the concept of self-care, how it relates to one’s sense of self-worth, and self-care in 
thecontext of one’s sexual health and HIV status (i.e. safer sex and healthcare seeking behaviors) 
2 
Looking 
Good, 
Feeling 
Good 
Discuss gender affirmation and how it affects self-image, self-care, and power to negotiate safer 
behaviors 
Discuss transition-related health care (i.e. hormone use/access, dangers of injection silicone use, safer 
injection practices) 
How taking care of your physical health (e.g., nutrition, sleep, HIV) leads to feeling good about oneself 
3 
Let’s Talk 
About Sex 
Provide accurate information on HIV/STI rates and risk factors among transgender women  
Discuss protection of oneself and one’s partners in the context of gender affirmation  
Discuss the importance of knowing one’s status and getting treatment if HIV-positive or STI-positive 
Offer referrals to transgender-friendly HIV/STI testing and treatment services; discuss barriers to 
testing and treatment and brainstorm solutions 
4 
Taking 
Back the 
Power 
Discuss how transphobia impacts one’s sense of personal power and explore ways to reclaim one’s 
power  
Explore assertiveness skills, practice negotiating safer behaviors and communicating with health care 
providers 
Provide an introduction to basic self-defense information and resources to increase skills for coping 
with transphobic harassment and violence 
5 
Surviving 
and 
Thriving 
Discuss how knowing one’s status and getting treatment for HIV is vital to self-care 
Discuss healthy ways of coping with transphobia in relationships and the stress of sex work 
Consider the effect of substance use on self-care and protection of one’s own and partners’ sexual 
health; offer resources and support for addressing substance use and mental health issues 
Celebrate oneself and trans communities as a vital source of social support; reinforce gender pride 
   
Table 1. Sample baseline characteristics 
Characteristic 
Total  
N (%) 
Treatment 
Group 
N (%) 
Control 
Group 
N (%) 
p-value 
Age  (mean/std) 38.9 (10.6) 40.1 (10.9) 37.8 (10.2) 0.47 
Gender identity    0.26 
 Female 36 (46.8) 21 (53.9) 15 (39.5)  
 Transgender female 36 (46.8) 17 (43.6) 19 (50.0)  
 Other 5 (6.5) 1 (2.6) 4 (10.5)  
Race/ethnicity    0.60 
 African American/black 38 (49.4) 18 (46.2) 20 (52.6)  
 White 16 (20.8) 7 (18.0) 9 (23.7)  
 Latina 8 (10.4) 4 (10.3) 4 (10.5)  
 Other 15 (19.5) 10(26.6) 5 (13.2)  
Undocumented immigrant 3 (3.9) 3 (7.7) 0 (0) 0.24 
Education    0.68 
 Less than high school 18 (23.4) 10 (25.6) 8 (21.1)  
 HS grad/GED 29 (37.7) 16 (41.0) 13 (34.2)  
 Tech/vocational school/some college 21 (27.3) 10 (25.6) 11 (29.0)  
 College degree or above 9 (11.7) 3 (7.7) 6 (15.8)  
Recent homelessness    0.39 
 Never homeless 9 (11.8) 7 (18.0) 2 (5.4)  
 Longer than a year ago 28 (36.8) 14 (35.9) 14 (37.8)  
 Between 6 and 12 months 10 (13.2) 6 (15.4) 4 (10.8)  
 Between 1 and 6 months 6 (7.9) 3 (7.7) 3 (7.7)  
 Within the past month 23 (30.7) 9 (23.1) 14 (37.8)  
HIV positive 35 (45.5) 18 (46.2) 17 (44.7) 0.90 
History of ART (if (HIV+) 29 (85.3) 16 (88.9) 13 (81.3) 0.53 
Current ART use (if (HIV+) 28 (82.4) 15 (83.3) 13 (81.3) 0.87 
Newly diagnosed (< 1 year) 1 (2.9) 0 (0) 1 (5.9) 0.49 
Years living with HIV  (mean/std) 13.4 (8.3) 14.3 (8.3) 12.4 (8.5) 0.43 
 
Table 3. Estimated Means (Standard Errors) of Sexual Behavior and Social Support Outcomes  
 
 Condomless Sex Partnersb Total Sex Partnersc Social Supportd 
Time Control Intervention Control Intervention Control Intervention 
Baseline 3.39 (1.16) 4.60 (1.55) 8.93 (3.59) 6.10 (2.40) 0.28 (0.09) 0.28 (0.08) 
3 Months 1.62 (0.76) 1.91 (0.86) 2.92 (1.36) 3.45 (1.57) 0.36 (0.10) 0.35 (0.10) 
6 Months 1.57 (0.82) 1.15 (0.56) 5.18 (2.72) 2.73 (1.41) 0.40 (0.14) 0.57 (0.13) 
p-valuea .169 .007 .001 .049 .522 .044 
 
a Test of simple main effect of overall time difference within group (2 degree of freedom test) 
b n=42 HIV-negative participants. Group-by-time interaction p=.67.  
c n=34 HIV-positive participants. Group-by-time interaction p=.31.  
d n=41 HIV-negative participants. Group-by-time interaction p=.67.  
 
